Back to Dashboard








Merck & Company, Inc. (MRK)
Real-time intraday values
Market Overview
From:
To:
MRK Intraday
No data available
SymbolMRK
IPO DateJan 2, 1962
CEOMr. Robert M. Davis J.D.
Full Time Employees73k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +0.67% | +0.89 US$ |
| 5 Days | -9.52% | -14.06 US$ |
| 1 Month | -10.80% | -16.18 US$ |
| 6 Months | +9.22% | +11.29 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of MRK...
Key Statistics
Market Cap
329.65B
P/E Ratio
135.07
Div Yield
2.65%
52W High
$156.92
52W Low
$95.36
Analyst Consensus
ConsensusBuy
Bullish1967.9%
Neutral932.1%
Bearish00.0%
52W Analyst Price Targets
Min Target
$105.00
$105.00
Max Target
$186.00
$186.00
Current$133.70
Avg Target$161.53
Analyst Recommendations
Target Price:$161.53($105.00 - $186.00)
Looking for more stocks? Explore them in the screener
Community Thoughts
Share your analysis and sentiment on MRK
Join the community to share your analysis
Latest News for MRK

What A Cancer Vaccine Stumble Means For Moderna Stock
Trefis•Nov 20, 2026, 06:29 PM

What Does Eli Lilly Offer That Merck Does Not?
Trefis•Nov 20, 2026, 04:59 PM

MSD and Isomorphic join forces to develop oncology drugs
Pharmaceutical Technology•Nov 20, 2026, 03:59 PM

HIV Clinical Trials - Global Strategic Business Report 2026-2032 Featuring Strategic Intelligence on Gilead, ViiV Healthcare, Merck, and Pfizer
GlobeNewswire•Nov 20, 2026, 03:19 PM


Should You Buy Bristol Myers Squibb Stock At Today's Discount?
Trefis•Nov 20, 2026, 02:51 PM

HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Zacks•Nov 20, 2026, 02:10 PM

Which Merck ETF Best Balances Its Drug Upside And Risks?
Simply Wall St.•Nov 20, 2026, 01:08 PM
Merck Says Sac-TMT Meets Endpoint of Overall Survival in Phase 3 Trial
MT Newswires•Nov 20, 2026, 12:20 PM
